Is Sodium Valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 7, 2014, Pages 759-767

  Dregan, Alex ^a,b   Charlton, Judith ^a   Wolfe, Charles D A ^a,b   Gulliford, Martin C ^a,b   Markus, Hugh S ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antiepileptic drugs; Epilepsy; Histone deacetylase (HDAC) inhibitors; Ischemic stroke; Myocardial infarction; Pharmacoepidemiology; Sodium valproate

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CARBAMAZEPINE; NEUROLEPTIC AGENT; PHENYTOIN; VALPROIC ACID; HISTONE DEACETYLASE INHIBITOR;

AGED; ANTICONVULSANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DATA EXTRACTION; ELECTRONIC MEDICAL RECORD; EPILEPSY; FEMALE; HEART INFARCTION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; CASE CONTROL STUDY; FACTUAL DATABASE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK; STATISTICAL BIAS; STATISTICAL MODEL; STROKE; SURVIVOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIAS (EPIDEMIOLOGY); BRAIN ISCHEMIA; CASE-CONTROL STUDIES; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; EPILEPSY; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK; STROKE; SURVIVORS; VALPROIC ACID;

EID: 84903815616     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3651     Document Type: Article

References (29)

1. International Stroke Genetics C, Wellcome Trust Case Control C, Bellenguez C, et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Gen 2012; 44: 328-333.
2. Traylor M, Farrall M, Holliday EG, et al. Genetic risk factors for ischaemic stroke and its subtypes (the metastroke collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 2012; 11: 951-962.
3. Markus HS, Makela KM, Bevan S, et al. Evidence HDAC9 genetic variant associated with ischemic stroke increases risk via promoting carotid atherosclerosis. Stroke 2013; 44: 1220-1225.
4. Lv L, Sun Y, Han X, Xu CC, Tang YP, Dong Q. Valproic acid improves outcome after rodent spinal cord injury: potential roles of histone deacetylase inhibition. Brain Res 2011; 1396: 60-68.
5. Bowes AJ, Khan MI, Shi Y, Robertson L, Werstuck GH. Valproate attenuates accelerated atherosclerosis in hyperglycemic apoe-deficient mice: evidence in support of a role for endoplasmic reticulum stress and glycogen synthase kinase-3 in lesion development and hepatic steatosis. Am J Pathol 2009; 174: 330-342.
6. Olesen JB, Abildstrom SZ, Erdal J, et al. Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study. Pharmacoepidem Dr S 2011; 20: 964-971.
7. Olesen JB, Hansen PR, Abildstrom SZ, Andersson C, Weeke P, Schmiegelow M, et al. Valproate attenuates the risk of myocardial infarction in patients with epilepsy: a nationwide cohort study. Pharmacoepidem Dr S 2011; 20: 146-153.
8. Pylvanen V, Knip M, Pakarinen AJ, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003; 60: 571-574.
9. Consortium CAD, Deloukas P, Kanoni S, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Gen 2013; 45: 25-33.
10. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004; 24: 8467-8476.
11. Hollowell J. The general practice research database: quality of morbidity data. Pop Trends 1997; 87: 36-40.
12. Dregan A, Toschke MA, Wolfe CD, et al. Utility of electronic patient records in primary care for stroke secondary prevention trials. BMC Public Health 2011; 11: 86-94.
13. Toschke AM, Gulliford MC, Wolfe CD, Rudd AG, Heuschmann PU. Antihypertensive treatment after first stroke in primary care: results from the general practitioner research database. J Hypertens 2011; 29: 154-160.
14. Nicholas JM, Ridsdale L, Richardson MP, Ashworth M, Gulliford MC. Trends in antiepileptic drug utilisation in UK primary care 1993-2008: cohort study using the general practice research database. Seizure 2012; 21: 466-470.
15. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Env Med 2004; 61: e59-e63.
16. Gulliford MC, Charlton J, Rudd A, Wolfe CD, Toschke AM. Declining 1-year case-fatality of stroke and increasing coverage of vascular risk management: population-based cohort study. J Neurol Neurosur Ps 2010; 81: 416-422.
17. Bhattarai N, Charlton J, Rudisill C, Gulliford MC. Coding, recording and incidence of different forms of coronary heart disease in primary care. PLoS One 2012; 7: e29776-e29781.
18. Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet 2004; 363: 1184-1186.
19. Huberman M, Langholz B. Application of the missing-indicator method in matched case-control studies with incomplete data. Am J Epidemiol 1999; 150: 1340-1345.
20. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009; 338: b2393.
21. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-46.
22. Greenland S. Multiple comparisons and association selection in general epidemiology. Int J Epidemiol 2008; 37: 430-434.
23. Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol 2009; 8: 1019-1030.
24. Moran NF, Poole K, Bell G, et al. Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. Seizure 2004; 13: 425-433.
25. Giuliani G, Terziani S, Senigaglia AR, Luccioni G, Foschi N, Maffei C. Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. Acta Neurol Scandinav 1992; 85: 23-31.
26. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005; 5: 5-10.
27. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366-1369.
28. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-481.
29. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45(Suppl 6): 13-18.